Literature DB >> 23161460

Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.

A Ghezzi, M A Rocca, D Baroncini, P Annovazzi, M Zaffaroni, G Minonzio, G Comi, M Filippi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23161460     DOI： 10.1007/s00415-012-6744-7

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  9 in total

1.  Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

Authors:  T A Yednock; C Cannon; L C Fritz; F Sanchez-Madrid; L Steinman; N Karin
Journal:  Nature       Date:  1992-03-05       Impact factor: 49.962

Review 2.  Secondary progressive multiple sclerosis: current knowledge and future challenges.

Authors:  Marco Rovaris; Christian Confavreux; Roberto Furlan; Ludwig Kappos; Giancarlo Comi; Massimo Filippi
Journal:  Lancet Neurol       Date:  2006-04       Impact factor: 44.182

Review 3.  Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.

Authors:  Jens Ingwersen; Orhan Aktas; Patrick Kuery; Bernd Kieseier; Alexey Boyko; Hans-Peter Hartung
Journal:  Clin Immunol       Date:  2011-05-26       Impact factor: 3.969

4.  Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.

Authors:  Claus Michael Gross; Annette Baumgartner; Sebastian Rauer; Oliver Stich
Journal:  Neurology       Date:  2012-10-03       Impact factor: 9.910

5.  Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.

Authors:  Bahia Hakiki; Emilio Portaccio; Marta Giannini; Lorenzo Razzolini; Luisa Pastò; Maria Pia Amato
Journal:  Mult Scler       Date:  2012-07-24       Impact factor: 6.312

6.  Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.

Authors:  Augusto Miravalle; Rikke Jensen; R Philip Kinkel
Journal:  Arch Neurol       Date:  2010-10-11

7.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

8.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

9.  Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.

Authors:  Joachim B Havla; Hannah L Pellkofer; Ingrid Meinl; Lisa Ann Gerdes; Reinhard Hohlfeld; Tania Kümpfel
Journal:  Arch Neurol       Date:  2012-02
  9 in total
  11 in total

1.  Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study.

Authors:  Pengxiang Li; Tianyan Hu; Xinyan Yu; Salim Chahin; Nabila Dahodwala; Marissa Blum; Amy R Pettit; Jalpa A Doshi
Journal:  Health Serv Res       Date:  2017-07-24       Impact factor: 3.402

2.  Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.

Authors:  E Piscolla; B Hakiki; L Pastò; L Razzolini; E Portaccio; M P Amato
Journal:  J Neurol       Date:  2013-05-05       Impact factor: 4.849

3.  Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.

Authors:  Loredana La Mantia; Valentina Prone; Maria Raffaella Marazzi; Cristina Erminio; Alessandra Protti
Journal:  Neurol Sci       Date:  2014-04-23       Impact factor: 3.307

4.  Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.

Authors:  Jean-Baptiste Davion; M Cambron; E Duhin; A Chouraki; A Lacour; P Labauge; C Carra; X Ayrignac; P Vermersch
Journal:  J Neurol       Date:  2016-05-09       Impact factor: 4.849

5.  Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?

Authors:  R Alroughani; A Almulla; S Lamdhade; A Thussu
Journal:  BMJ Case Rep       Date:  2014-10-15

Review 6.  An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis.

Authors:  Marzia Fronza; Lorena Lorefice; Jessica Frau; Eleonora Cocco
Journal:  Drug Des Devel Ther       Date:  2021-05-11       Impact factor: 4.162

Review 7.  Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alberto Gajofatto; Marco Turatti; Salvatore Monaco; Maria Donata Benedetti
Journal:  Drug Healthc Patient Saf       Date:  2015-12-11

Review 8.  Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations.

Authors:  Ilya Ayzenberg; Robert Hoepner; Ingo Kleiter
Journal:  Ther Clin Risk Manag       Date:  2016-02-19       Impact factor: 2.423

Review 9.  Neurological safety of fingolimod: An updated review.

Authors:  Fumihito Yoshii; Yusuke Moriya; Tomohide Ohnuki; Masafuchi Ryo; Wakoh Takahashi
Journal:  Clin Exp Neuroimmunol       Date:  2017-06-18

Review 10.  Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.

Authors:  Jong-Mi Lee; May H Han
Journal:  Patient Prefer Adherence       Date:  2015-05-21       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.